NIH VideoCast - Past and Future Therapy for Hepatitis C

Skip Navigation

Past and Future Therapy for Hepatitis C

Loading... Loading video...

364 Views

Air date:	Wednesday, November 12, 2014, 3:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 364 (107 Live, 257 On-demand)
Category:	WALS - Wednesday Afternoon Lectures
Runtime:	00:53:03
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	Wednesday Afternoon Lecture Annual Astute Clinician Lecture The Astute Clinician series honors a U.S. clinician-scientist who has observed an unusual clinical occurrence, and by investigating it, has opened an important new avenue of research. Dr. Jay H. Hoofnagle, an expert in liver diseases, has been involved in early evaluation and development of virtually all antiviral agents developed for viral hepatitis including interferon, ribavirin, lamivudine and adefovir dipivoxil. He has studied Hepatitis C, the most critical area of all liver disease research, for over 30 years. Dr. Hoofnagle will discuss the hepatitis C virus, new insights in how it harms the liver, and new developments of new direct acting antivirals that now promise to cure the majority of patients with this very important liver disease. For more information go to http://wals.od.nih.gov

NLM Title:	Past and future therapy for hepatitis C / Jay H. Hoofnagle.
Author:	Hoofnagle, Jay H. National Institutes of Health (U.S.),
Publisher:
Abstract:	(CIT): Wednesday Afternoon Lecture Annual Astute Clinician Lecture The Astute Clinician series honors a U.S. clinician-scientist who has observed an unusual clinical occurrence, and by investigating it, has opened an important new avenue of research. Dr. Jay H. Hoofnagle, an expert in liver diseases, has been involved in early evaluation and development of virtually all antiviral agents developed for viral hepatitis including interferon, ribavirin, lamivudine and adefovir dipivoxil. He has studied Hepatitis C, the most critical area of all liver disease research, for over 30 years. Dr. Hoofnagle will discuss the hepatitis C virus, new insights in how it harms the liver, and new developments of new direct acting antivirals that now promise to cure the majority of patients with this very important liver disease.
Subjects:	Antiviral Agents Hepacivirus--drug effects Hepatitis C--drug therapy
Publication Types:	Lecture Webcast

NLM Classification:	WC 536
NLM ID:	101647967
CIT Live ID:	15134
Permanent link:	https://videocast.nih.gov/watch=15134

Related Videos...